Introduction
Over the past decade, successful translation of immunotherapeutic agents to the clinic with remarkable response rates in solid tumors, including lung cancer, has reinvigorated interest in further exploiting the discoveries in tumor immunology. Immunotherapy uses and/or activates components of the immune system, such as antibodies, dendritic cells, and T lymphocytes, to treat cancer. The first documented attempt of immune stimulation as a cancer treatment was by Dr. William Coley in 1893. Dr. Coley treated patients diagnosed with sarcoma and carcinoma using cultures of Streptococcus pyogenes. 1 This approach was based on this pioneering New York surgeon's observation of occasional tumor regression after acute infections. Dr. Coley treated more than 900 patients with Coley's toxins and achieved a response rate of approximately 10% more than a century ago. 2 Despite the promising results, these findings were not adopted by the scientific community and remained unexplored.
Further advances in tumor immunology occurred in the 1950s, when preclinical studies showed that the immune system can induce tumor regression in mice. 3 In 1967, Burnet proposed the theory of immunosurveillance, which states that the immune system can recognize and eliminate initial tumor cells. 4 This theory was confirmed years later in immunodeficient strains of mice that lacked expression of granzyme B (a protein necessary for the cytotoxic activity of CD8-positive T lymphocytes) and in mice without B and T lymphocytes (Rag knockout mice); these animals have an increased rate of tumor formation compared with wild-type animals. 5, 6 In contrast to the role of the immune system in tumor control and eradication, it was clear that this also allows tumor development by selected clones with increased ability to escape from immune recognition and elimination. This paradoxical process was termed cancer immunoediting and has three phases-elimination, equilibrium, and escape-that were confirmed in murine and human models.
Adoptive T-Cell Therapy
The observation that donor-derived T cells are able to control leukemia after hematopoietic stem cell transplantation and the demonstration that the immune system can recognize and kill tumor cells in vivo through T-lymphocyte activity has prompted researchers to develop protocols for isolation and expansion of tumorreactive T cells and use these cells as treatment by adoptively infusing them back into patients; this process is termed adoptive T-cell therapy. The first such approach was developed in the 1990s and involved the isolation and expansion of tumor-infiltrating lymphocytes (TILs) from tumors of patients with advanced melanoma. TILs have been shown to recognize and kill tumor cells in vitro and can be expanded using anti-CD3/CD28 antibodies in the presence of interleukin-2 (IL-2). Whereas the initial studies involved only the infusion of T cells, which achieved limited responses, 8 subsequent studies combined T cells with a nonmyeloablative preconditioning regimen designed to induce lymphodepletion. This combination induced clinical responses in 51% of patients, 9 which indicated that the preconditioning regimen lowered the competition for cytokines by endogenous T cells and favored the proliferation and survival of the infused T cells. 10 However, TIL cultures cannot be generated for all melanomas nor for other tumor types in cases in which there are not enough TILs or TILs do not recognize the tumor, which limits the applicability of this therapy. Advances in cellular and molecular biology have allowed isolation of responding T-cell clones as well as identification and sequencing of their T-cell receptor (TCR). The TCR is responsible for recognition of peptides bound to the major histocompatibility complex (MHC) and activation of lymphocytes. Cloning the TCR sequence in viral vectors and transducing T lymphocytes isolated from peripheral blood can generate large numbers of tumorspecific T cells without the cumbersome process of isolation and expansion of TILs. TCRs that recognize tumor antigens have been identified and used in clinical trials to treat tumors such as melanoma and synovial sarcoma.
11 High-throughput analysis of TILs, in combination with deep sequencing of the autologous tumor, has led to T-cell therapy that targets tumor neoantigens arising from mutations. 12 Despite facilitating the generation of tumor-specific T cells, TCR immunotherapy is limited by MHC restriction in which each TCR recognizes a specific MHC haplotype. This means that expansion of TCR immunotherapy would involve the identification and cloning of a large number of TCRs to cover the most-represented haplotypes in different patient populations; this would, in turn, increase the complexity of the therapy. Moreover, tumors generally down-regulate MHC class I as an escape mechanism and become resistant to this type of therapy. 13 These limitations can be overcome with use of chimeric antigen receptors (CARs). CARs are synthetic membrane receptors that activate T lymphocytes upon interaction with the target antigen (Table 1). 14 These receptors were first developed by Eshhar et al. 15 and have a structure comprising an antigen-binding domain that is commonly a single-chain variable fragment (scFv) derived from an antibody, a transmembrane domain, and an intracellular signaling domain. The scFv confers high specificity and affinity and allows for binding to the antigen that is expressed on the membrane of the target cell in a MHC-independent fashion (Fig. 1) . Over the past two decades, CAR T cells have evolved from the first generation, which contained only a signaling domain, such as the TCR-derived CD3z chain, to the second and third generations, which have incorporated costimulatory domains such as CD28 and 4-1BB. These costimulatory domains recruit downstream effector molecules that result in the activation of multiple signaling pathways and lead to increased proliferation and improved functional persistence (Fig. 2) .
CAR T-Cell Therapy Clinical Successes
The first clinical trials that evaluated CAR T cells targeting CD19-positive hematologic malignancies, such as acute lymphocytic leukemia (ALL), diffuse large B-cell lymphoma, follicular lymphoma, and mantle cell lymphoma, showed remarkable response rates; 68% to 100% of patients with ALL achieved complete remission. 16 More importantly, these studies included relapsed, chemotherapy-refractory patients and made use of second-generation anti-CD19 CARs. Promising results have also been achieved with anti-CD22 CAR T cells in pediatric patients with CD22-expressing ALL that relapsed because of CD19 antigen loss in tumor escape variants after previously receiving anti-CD19 CAR T cells. 17 CAR T-cell therapy for hematologic malignancies uses cytotoxic, preconditioning lymphodepletion, without which the clinical benefits would be limited. The dramatic responses observed were not without toxicities such as cytokine release syndrome (CRS) and neurotoxicity with deaths from cerebral edema. T-cell mediated immune activation leads to elevation of inflammatory cytokines, in some cases resulting in severe CRS with manifestations of fever, hypotension, capillary leak, cardiac dysfunction, renal impairment and hepatic failure. 18 While CRS is managed effectively by administering interleukin receptor-6 blockade agents or corticosteroids, the mechanism of neurotoxicity remains elusive. 18 Novel CAR designs that incorporate suicide genes as molecular safety switches that can be activated to kill infused CAR T cells are already in use in clinical trials to manage unexpected severe adverse events and inhibitory CARs that selectively reduce T-cell function upon off-target interaction are in preclinical development. 19 The manufacturing of autologous CAR T cells represents a multifaceted process that involves the collection of peripheral blood mononuclear cells from patients by means of apheresis, enrichment and activation of T cells, gene transfer and ex vivo expansion of CAR T cells, endof-process formulation, and release testing. 20 The chimeric receptor itself can be introduced into the T cell either through stable insertion into the genome using viral (retroviral or lentiviral)-and nonviral (transposon)-based gene expression vectors or using mRNA for transient expression of the transgene. 20 Allogeneic donor-derived T cells with gene-edited TCR have the potential to streamline the manufacturing process and to generate off-the-shelf CAR T cells. 21 Despite differences in CAR T-cell antigen binding and costimulatory domains, gene transfer methods, and manufacturing processes across different clinical centers, there was a very high rate of success in eradication of hematologic malignancies in most phase I clinical trials. 15 These successes have paved the way for translating CAR T-cell therapy to solid tumors, including thoracic malignancies.
Rationale for Promoting TILs in Thoracic Malignancies
Publications from our laboratory and others have demonstrated the survival benefits associated with a higher ratio of effector to suppressive TILs in lung adenocarcinoma (ADC), 22 lung squamous cell carcinoma, 23 and malignant pleural mesothelioma (MPM).
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These observations, combined with recent successes and development of strategies to increase functional TILs in NSCLC underscore the need to promote antigenspecific T-cell responses in thoracic tumors. 25 Unlike in hematologic malignancies, in which CD19 has been an ideal target for CAR T-cell therapy, identification of an ideal target for thoracic malignancies is challenging.
Targets for CAR T-Cell Therapy in Clinical Trials for Thoracic Malignancies
The ideal target for CAR T-cell therapy is either exclusively expressed or overexpressed on all or most tumor cells with no or very limited expression on normal tissue. Targets for CAR T-cell therapy for thoracic malignancies that are currently being evaluated include the following: overexpressed or aberrantly expressed antigens (EGFR, human epidermal growth factor receptor 2 (Fig. 3) . Clinical studies investigating CAR T cells for thoracic malignancies are listed in Table 2 .
In contrast to CD19, which is a B-cell lineage-specific target and is consistently expressed in leukemia, most solid tumor antigen targets are also expressed at low levels on healthy tissue and may lead to on-target/off-tumor effects. A fatal adverse event of pulmonary toxicity was reported by Morgan et al. 26 for a patient with colon cancer that metastasized to the lungs and liver immediately after administration of 1 Â 10 10 HER2-targeted CAR T cells; it was ascribed to HER2 expression in the lung epithelium. A subsequent dose-escalation phase I/II study established feasibility and safety of administering HER2-targeted CAR T cells (10 ) to patients with recurrent or refractory HER2-positive tumors; however, the clinical benefit was limited, as only 4 of 17 evaluable patients had stable disease. 27 No dose-limiting toxicity was reached in this study which is in contrast to the observations from Morgan and colleagues, however, significant differences between the two studies exist regarding dosage, lymphodepletion and IL-2 regimen as well as variation within the CAR structure itself. Baylor College of Medicine, Southwest Hospital in China, and the Chinese People's Liberation Army General Hospital are currently conducting further clinical studies of HER2-targeted CAR T cells to test their safety and efficacy for HER2-positive solid tumors, including lung and esophageal cancer.
EGFR, along with HER2, belongs to the ErbB family of receptor tyrosine kinases and is an established target for antibody-based therapies and receptor tyrosine kinase inhibitors. The clinical response of EGFR-directed CAR T cells was investigated in a phase I study (NCT01869166) in patients with relapsed/refractory NSCLC with EGFR expression of 50% or more (as determined by immunohistochemistry). Two of 11 patients had a partial response and five patients had stable disease after infusion of a median dose of 0.97 Â 10 7 CAR T cells/kg. This study also showed that patients who received no benefit from receptor tyrosine kinase inhibitor therapy can benefit from CAR T-cell therapy. 28 MSLN is a cell surface glycoprotein that is expressed at very low levels on normal mesothelial cells of the pleura, peritoneum, and pericardium. Our laboratory and others 29 have shown that MSLN is overexpressed on cancer cells in 80% to 90% of MPM, 30 40% to 60% of lung ADC, 31 36% of triple-negative breast cancer, 32 40% of esophageal cancer, 33 and 79% of thymic cancer. 34 Overexpression of MSLN is correlated with tumor aggressiveness, KRAS mutation positivity, and decreased survival in lung ADC. 31 Additionally, we have shown that MSLN expression correlates with invasion in MPM 30 and malignant transformation in Barrett's esophagus. 33 This justifies our rationale for targeting MSLN in thoracic tumors. A case from a clinical trial (NCT01355965) conducted by the University of Pennsylvania to test the safety and feasibility of repetitive intravenous or intratumoral administration of mRNA-engineered T cells that transiently expressed an anti-MSLN CAR did not reveal evidence of off-tumor toxicities; however, epitope spreading was observed as a result of the antitumor efficacy. An anaphylactic event caused by immunogenicity against the scFv of murine origin occurred after repeated infusions. 35 Our laboratory has developed a CAR construct with a fully human scFv that targets MSLN and exerts long-lasting tumor immunity after regional administration of MSLN-targeted, second-generation CAR T cells in an orthotopic mouse model of human pleural disease. 36 On the basis of our preclinical data on enhanced antitumor efficacy after regional rather than systemic administration of CAR T cells, we are conducting a phase I clinical trial to evaluate the safety of regionally administered MSLN-targeted CAR T cells in patients with primary or secondary pleural malignancies (NCT02414269).
GPC3, EpCAM, and PSCA are additional tumorassociated antigens that are overexpressed in tumors cells and are currently being investigated as CAR T-cell targets for thoracic malignancies. GPC3 was present in 66% of lung squamous cell carcinoma and 3.3% of lung ADC samples but not in normal lung tissue, 37 and it has been targeted in two clinical studies (NCT02876978 and NCT03198546). EpCAM overexpression is associated with poor survival in patients with esophageal squamous cell carcinoma 38 and explored as a target for CAR T-cell therapy for esophageal cancers (NCT03013712). PSCA is being studied in one clinical trial (NCT03198052) as a candidate target, and a recent study in patient-derived xenograft mouse models suggests that dual targeting of PSCA and MUC1 can synergistically enhance antitumor efficacy in NSCLC. 39 Tumor-selective antigens that arise from deregulated posttranslational modifications, such as MUC1, provide another class of targets for immunotherapy. MUC1 is found aberrantly glycosylated in multiple ADCs and is associated with poor overall survival in patients with NSCLC. 40 Currently, two ongoing clinical trials are using MUC1-targeted CAR T cells to treat patients with lung cancer (NCT02587689 and NCT03198052).
Oncofetal antigens comprise a class of targets that are typically present only during fetal development but are also found on some cancer variants in adults. A phase I clinical trial (NCT01212887) of first-generation CEA-specific CAR T cells with preconditioning chemotherapy and intravenous IL-2 in patients with CEApositive solid tumors was terminated. The reasons for termination included lack of efficacy due to poor persistence of the CAR T cells and preconditioningdependent respiratory toxicity presumably caused by off-tumor expression of CEA on normal lung epithelium. 41 Another ongoing clinical trial targeting CEA in lung cancer and other solid tumors (NCT02349724) is using a second-generation CAR T-cell and has shown encouraging results in patients with CEA-positive metastatic colorectal cancer. 42 The receptor tyrosine kinase ROR1 is an oncofetal antigen overexpressed in lung ADC and is an independent prognostic biomarker for overall survival. 43 Fred Hutchinson Cancer Research Center is currently conducting a phase I clinical trial of CAR T cells in patients with stage IV ROR1-positive NSCLC (NCT02706392).
Another appealing strategy for CAR T-cell therapy is to simultaneously target tumor and associated stroma cells. A potential target is FAP, and it is expressed in all of the major MPM histologic subtypes (epithelioid, sarcomatoid, and biphasic), as well as in the tumor stroma. On the basis of this observation, Schubert et al. developed an intraperitoneal xenograft model for testing FAPspecific CAR T cells and showed that treated mice bearing FAP-positive tumors had a significant survival benefit. 44 This provided the rationale for a clinical trial testing the safety of a single dose of 1 Â 10 6 FAP-specific T cells administered directly into the pleural effusion (NCT01722149). Recent research has shown that FAPtargeting CAR T cells disrupt stromagenesis, diminish tumor angiogenesis and may increase immune cell infiltration in highly desmoplastic tumors. 45 Conversely, a preclinical study raised concerns of possible bone toxicity on account of the strong expression of FAP on bone marrow stromal cells. 46 There are currently two clinical trials (NCT03198052 and NCT03060343) targeting PD-L1 and CD80/CD86 in lung cancer. Although antibodies blocking the PD-1/ PD-L1 pathway (checkpoint inhibitors) are being successfully used in the clinic to treat lung cancer, 47 no preclinical data exist for CAR T cells that target PD-L1. CD80 and CD86, which are expressed on the surface of antigen-presenting cells, either bind to CD28 on T cells and provide the costimulatory signal necessary for T-cell activation or depending on the context, lead to downregulation of T-cell activity by binding to cytotoxic T-lymphocyte antigen 4. 48 Little is known about CD80/ CD86 expression on lung tumor cells, and because of the expression of CD80/CD86 and PD-L1 on normal immune cells, possible on-target/off-tumor toxicities need to be carefully elucidated.
It is noteworthy to mention that CAR T cells can also be engineered to target intracellular antigens. This is exemplified by the CAR T cells that bind to a peptide epitope from the zinc finger transcription factor WT1 that is presented in the context of MHC on the cell surface.
14 This work provided proof of concept that the scope of possible CAR targets can be expanded beyond surface antigens. Note: These are clinical studies listed on ClinicalTrials.gov (last assessed on July 20, 2017) that specifically defined thoracic tumors in the inclusion criteria or study outline. a The study has been terminated because of lack of efficacy and safety concerns. The study is suspended because of funding. The study is active but not recruiting. The study has been completed. ADC, adenocarcinoma; CEA, carcinoembryonic antigen; EGFR, epidermal growth factor receptor; EpCAM, epithelial cell adhesion molecule; FAP, fibroblast activating protein; GPC3, glypican-3; HER2, human epidermal growth factor receptor 2; ID, identifier; LSCC, lung squamous cell carcinoma; MSLN, mesothelin; MPM, malignant pleural mesothelioma; MUC1, mucin 1; NSCLC, non-small cell lung cancer; PD-L1, programmed death-ligand 1; PLA, People's Liberation Army; PSCA, prostate stem cell antigen; ROR1, receptor tyrosine kinase-like orphan receptor 1; UK, United Kingdom.
Hurdles in Successful Translation of CAR T-Cell Therapy for Solid Tumors
Despite the encouraging clinical results in hematologic malignancies, successful use of CAR T cells for the treatment of solid tumors has proved to be challenging. Although several T-cell parameters can still be optimized, it is clear that tumor-intrinsic mechanisms and the associated tumor microenvironment have an important role in the inhibition of antitumor response. Although most of the approaches to overcome the solid tumor barriers are still in preclinical phase, emerging strategies center around addressing antigen heterogeneity, improving CAR T-cell trafficking and tumor infiltration, increasing resistance towards immunosuppressive immune cells and inhibitory soluble factors as well as preserving functional T-cell persistence by counteracting T-cell intrinsic suppressive mechanisms. Tumor cell heterogeneity that results from genomic instability induces the generation of clonal populations that harbor different mutations and antigen expressions and can facilitate the generation of escape variants upon CAR T-cell therapy. Variability of antigen expression on the surface of the tumor cell constitutes one of the major hurdles in CAR T-cell therapy, possibly rendering tumor cells with low antigen expression less susceptible to CAR T-cell therapy (Fig. 4A) . The use of T cells that target two antigens simultaneously can help prevent tumor evasion. 49 Despite the fact that this strategy may be hampered by the limited number of described antigens and potential on-target/off-tumor toxicity, ongoing studies are investigating its utility in the context of thoracic malignancies.
The successful trafficking of CAR T cells to the tumor site is dependent on the expression of adhesion molecules on the T-cell and tumor endothelium, as well as on chemokines secreted by the tumor that match the chemokine receptor expressed on the T-cell. 50 The fact that MPM secretes high levels of the chemokine C-C motif chemokine ligand 2 has provided the necessary evidence to generate CAR T cells that overexpress C-C motif chemokine receptor 2 (the receptor for C-C motif chemokine ligand 2), which have shown increased migration to the tumor and improved antitumor activity in a mesothelioma model. 51 Regional delivery of CAR T cells is another promising approach to bypass the pulmonary sequestration of lymphocytes. Our published observations that intrapleural administration of anti-MSLN CAR T cells yields long-term antitumor activity, even at 30-fold lower doses to achieve complete response in a preclinical model, 35 provides a clinically significant opportunity to treat pleural malignancies. The current annual incidence in the United States alone is 150 000 patients. 52 Administration of CAR T cells into the pleural space is currently being tested in clinical trials for MSLN-and FAP-targeted CAR T cells (NCT02414269 and NCT01722149).
Once trafficked to the tumor site, CAR T cells are exposed to anatomical and metabolic barriers. Cancerassociated stroma represents an anatomical barrier that CAR T cells need to overcome to successfully infiltrate the tumor (Fig. 4B) . Targeting stroma cells by using FAP-specific CAR T cells has been shown to increase CD8-positive T-cell infiltration and augment antitumor immunity by disrupting extracellular matrix components. 44 The limited supply of oxygen and nutrients found in the tumor microenvironment also affects the function of T lymphocytes. A glucose-poor microenvironment limits the capacity of effector T cells to engage in glycolysis and results in inhibition of effector functions and lower levels of the glycolytic metabolite phosphoenolpyruvate that sustains the Ca2-positive/ nuclear factor of activated T cell signaling essential for T-cell function. 53 By-products of metabolism, such as lactate, can also inhibit the activity of CD8-positive T cells. 54 Limited availability of amino acids, such as arginine, used by lymphocytes as an alternative source of energy for protein synthesis during the expansion phase of activated T cells also impairs T-cell function and antitumor activity. 55 Immunosuppressive cells found in the microenvironment of solid tumors also play an important role in resistance to T-cell therapy. Tumor-associated macrophages (M1 and M2 phenotype) are a large fraction of the infiltrating myeloid cells in MPM and lung cancer (Fig. 4C) . 56 Whereas M1 macrophages are associated with Th1 responses and antitumor activity, M2 macrophages are involved in angiogenesis and extracellular matrix remodelling. M2 macrophages inhibit differentiation to M1 macrophages and secrete several inhibitory cytokines, which results in inhibition of T-cell function when their frequency increases. 57, 58 Myeloid-derived suppressor cells are a heterogeneous population of immature myeloid cells that are also involved in inhibiting T-cell response by changing the amino acid composition in the tumor microenvironment and recruiting regulatory T cells (Tregs). 59 Tregs can also suppress T-cell function through direct cell-to-cell interaction, checkpoint regulation, or secretion of inhibitory cytokines. 60 Several soluble factors and cytokines secreted by the tumor and immunosuppressive cells have inhibitory effects on T cells. One of the best-studied factors is transforming growth factor b (TGF-b), and it has described roles in NSCLC, 61 mesothelioma, 62 and thymoma 63 progression. TGF-b induces the polarization of macrophages into a M2-like phenotype and, in the case of T lymphocytes, promotes Treg differentiation 64 and inhibits CD8-positive T-cell function. 65 Cytotoxic lymphocytes that overexpress a dominant negative TGF-b receptor were resistant to these inhibitory functions, 66 thereby providing a promising strategy to enhance CAR T-cell activity.
Both infiltrating myeloid cells and tumor cells express several inhibitory ligands in their membrane that can interact with T lymphocytes and inhibit their activation (Fig 4D) . One of the most studied is PD-L1, which is upregulated in response to interferon gamma signaling and interacts with the programmed cell death protein 1 (PD-1) inhibitory receptor on T cells. 47 Chronic PD-1 signaling in T lymphocytes induces an exhaustion phenotype that is characterized by decreased effector function and proliferation. Our group has shown that upon repeated antigen stimulation in vitro and in vivo, anti-MSLN CAR T cells become exhausted and upregulate PD-1. 67 Moreover, tumor cells up-regulate PD-L1 and PD-L2 in vivo after treatment with CAR T cells; this is directly related to the cytokines produced by the activated lymphocytes. The administration of PD-1-blocking antibodies can rescue infused T-cell activity; however, multiple doses are required. The use of a PD-1 dominant negative receptor coexpressed with a CAR enhanced T-cell function and increased tumor-free survival, while simultaneously avoiding repeated doses of blocking antibodies. 67 A similar strategy was used by Liu et al., who coexpressed a CAR with a switch receptor that harbored the extracellular domain of PD-1 and the transmembrane and intracellular domain of the costimulatory molecule CD28. The inhibitory PD-L1/PD-1 signaling was blocked while providing CD28 costimulation and led to augmented antitumor efficacy. 68 
Future Perspectives and Conclusion
With recent unanimous U.S. Food and Drug Administration approval of CD19-targeted CAR T cells for the treatment of patients with relapsed or refractory ALL (80%-90% overall response rates), CAR T-cell therapy for hematologic malignancies has become mainstream. Although treatment will be conducted at accredited treatment centers in the United States with staff who are appropriately trained on a comprehensive risk mitigation strategy, the advances in cell manufacturing and production, the efficient management of CRS, and the infrastructure for clinical implementation of CAR T-cell therapy are already well established. 69 The constant interplay between T cells, tumor cells, and cells present in the tumor microenvironment induces immunosuppressive networks that are reinforced, which ultimately inhibits the antitumor response. The aforementioned strategies were developed from understanding the solid tumor immune microenvironment, can help overcome the suppression of CAR T cells, and are being translated to the clinic. 70 Combination CAR T-cell therapy and checkpoint blockade has already been implemented by our group in the clinic, and agents that target the PD-1/PD-L1 axis mark only the beginning of many possible future combination regimens. 47 A more complete understanding of the dominant immunosuppressive pathways in thoracic malignancies will help us define the optimal CAR design in terms of antigen targeting, signaling domains, and additional genetic modifications to improve and sustain clinical responses in future studies. The study of additional inhibitory receptors, such as lymphocyte-activation gene 3 (LAG3) and T-cell immunoglobulin mucin family member 3 (TIM3), 71 may improve our understanding of immune activation and response and also provide new strategies in combination therapy. The integration of advances in T-cell biology, tumor biology, and the tumor microenvironment will provide us with the tools necessary to enhance CAR T-cell therapy function and efficacy and, ultimately, improve clinical responses of patients with thoracic malignancies.
